Abbott has announced a collaboration with AtaCor Medical to develop a next-generation extravascular implantable cardioverter defibrillator (EV-ICD) system.
The investigational system is designed to deliver life-saving defibrillation therapy while reducing risks linked to traditional ICDs.
AtaCor is a cardiac rhythm management company focused on extravascular defibrillation technologies. Through the collaboration, AtaCor’s investigational parasternal EV-ICD lead (Atala) will be paired with Abbott’s investigational ICD system.
The combined system keeps lead components outside the heart and vasculature.
Traditional ICD leads pass through veins and attach directly to the heart. This can lead to complications such as:
The Abbott–AtaCor EV-ICD system aims to avoid these long-standing challenges.
AtaCor’s Atala lead is placed through a rib space near the breastbone. The lead remains outside blood vessels while maintaining proximity to cardiac tissue. Its directional design is intended to:
AtaCor plans to initiate a pivotal Investigational Device Exemption (IDE) trial in 2026. The study, named ALARION EV Study, will evaluate the combined Abbott–AtaCor investigational EV-ICD system.
Randel Woodgrift, senior vice president, Abbott cardiac rhythm management, emphasized Abbott’s commitment to CRM innovation. He highlighted Abbott’s portfolio, spanning leadless pacemakers, conduction system pacing, and now next-generation EV-ICD technology.
Dr. Paul Friedman, chair of cardiovascular medicine at Mayo Clinic, called the system an important step forward. He noted its potential to deliver ICD therapy outside the heart while preserving effective cardiac contact.
The collaboration underscores Abbott’s focus on simpler, smarter cardiac rhythm management solutions.
By addressing unmet clinical needs, Abbott continues to expand options for physicians and patients.
Abbott is a global healthcare leader operating across:
Its mission is to help people live healthier lives at every stage of life.